August 18, 2010 -- GlaxoSmithKline will purchase an additional 9% of the vaccine-focused JV it shares with Shenzhen Neptunus Interlong Bio-technique. The price – $10.575 million – represents a 50% increase in valuation over the one established when the JV was formed last year. After the transaction, GSK will own 49% of the entity while Nep Interlong will hold the remaining 51%. More details....
